Analytical Data
-
Gene name
ITGA5
- Application
-
Alternative Names
CD49e; CD49-E; ITG-A5; FNRA; VLA5A; Fibronectin Receptor,Alpha Polypeptide; Integrin alpha-F; CD49 antigen-like family member E
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 85% as determined by SDS-PAGE.
-
Uniprot
P08648
-
Expression Region
Phe42~Asn664
-
Molecular Weight
71kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ITGA5, or Integrin Alpha 5, is a crucial protein that plays a significant role in cell adhesion, migration, and signaling processes, predominantly by interacting with fibronectin in the extracellular matrix. Its involvement in various physiological and pathological contexts, including wound healing, tissue repair, and tumor progression, has garnered particular interest in the field of biomedical research. Studies have shown that ITGA5 is upregulated in several types of cancer, making it a potential biomarker for tumorigenesis and a target for therapeutic interventions. Researchers aim to produce recombinant ITGA5 protein to better understand its structure-function relationship and its role in cellular processes. Additionally, the availability of this protein can facilitate the development of assays for drug screening and the exploration of signaling pathways. The recombinant form can be used in various applications, including functional assays to study its interactions with other proteins and potential inhibitors, contributing significantly to the understanding of its role in cancer biology and other diseases. The production and characterization of ITGA5 recombinant protein offer valuable insights into its mechanisms, enabling the development of targeted therapies that could enhance treatment outcomes for patients with integrin-related diseases. This research area holds promise for advancing our understanding of integrin-mediated processes and their therapeutic implications.
